Question 1

What is ZANUBRUTINIB used for?

Accepted Answer

ZANUBRUTINIB (brand name BRUKINSA) is a Targeted Cancer Therapy indicated for in combination with obinutuzumab, in combination with obinutuzumab.

Question 2

How does ZANUBRUTINIB work?

Accepted Answer

ZANUBRUTINIB works through the following mechanism: 12.1 Mechanism of Action Zanubrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). Zanubrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B-cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. In nonclinical studies, zanubrutinib inhibited malignant B-cell proliferation and reduced tumor growth..

Question 3

What are the most common side effects of ZANUBRUTINIB?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for ZANUBRUTINIB. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is ZANUBRUTINIB the same as BRUKINSA?

Accepted Answer

BRUKINSA is a brand name for ZANUBRUTINIB. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

ZANUBRUTINIB

Mechanism of Action

Indications

FDA Warnings

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations